5 recruiting, 2 completed, 1 active not recruiting, 1 unknown. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 5, Completed 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Allogeneic HSCT: new trials by email Literature Review of Allogeneic HSCT trials Research Report on Allogeneic HSCT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF) - Immunodeficiency, Hematopoietic Stem Cell Transplantation | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2023-02-23 | 2026-10-16 |
| The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation Melphalan, Sirolimus, Total Body Irradiation (TBI) - Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 260 | 2022-11-18 | 2026-11-06 |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2021-09-23 | 2026-11-09 |
| A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. Cytarabine, Busulfan, Cyclophosphamide - Leukemia, Graft-versus-host-disease | Phase 2 | Unknown | Yi Luo | 46 | 2020-12-03 | 2023-02-21 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Busulfan test dose, Fludarabine, Busulfan - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2020-09-22 | 2026-10-19 |
| Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL CD19/CD22 CAR-T - B-ALL | Phase 1 / Phase 2 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 50 | 2020-07-27 | 2023-02-22 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Allogeneic HSCT, Fludarabine, Melphalan - Multiple Myeloma | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 57 | 2015-08-01 | 2023-01-04 |
| Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations Allogeneic HSCT, Busulfan Test dose, Fludarabine (Fludara, Berlex Laboratories) - GATA2, Immunodeficiency | Phase 2 | Recruiting | National Cancer Institute (NCI) | 144 | 2013-07-24 | 2026-10-16 |
| Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT allogeneic HSCT - Multiple Myeloma | Phase 2 | Completed | Universitätsklinikum Hamburg-Eppendorf | 50 | 2002-11-01 | 2022-09-02 |
Autoimmune Diseases (2) · Hematologic Neoplasms (2) · Immunologic Deficiency Syndromes (2) · Multiple Myeloma (2) · Anemia, Refractory, with Excess of Blasts (1) · Bronchiolitis Obliterans Syndrome (1) · Common Variable Immunodeficiency (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Immune System Diseases (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoproliferative Disorders (1) · Myelodysplastic Syndromes (1) · Opportunistic Infections (1)
National Cancer Institute (NCI) (5) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Universitätsklinikum Hamburg-Eppendorf (1) · Yi Luo (1)
United States (6) · China (1) · Germany (1) · Russia (1)
Christopher G Kanakry, M.D. (2) · Bhavisha A Patel, M.D. (1) · Danielle E Pregent-Arnold, M.D. (1) · Mary Horowitz, MD (1) · Michael Maschan (1) · Nicolaus Kroeger, Prof. Dr. (1) · Sung-Yun Pai, M.D. (1) · Yi Luo (1)
PMID 19912215, PMID 32556286, PMID 35840087, PMID 36251488, PMID 37595058, PMID 41175032, PMID 41370196
U01HL069294 (1)